Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $12.95 and traded as high as $19.30. Capricor Therapeutics shares last traded at $18.45, with a volume of 652,168 shares changing hands.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an "overweight" rating and a $35.00 price target for the company. Oppenheimer reissued an "outperform" rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $24.67.
Get Our Latest Analysis on CAPR
Capricor Therapeutics Price Performance
The stock has a 50 day moving average price of $12.95 and a two-hundred day moving average price of $7.75.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Sell-side analysts forecast that Capricor Therapeutics Inc will post -1.17 earnings per share for the current year.
Insider Buying and Selling
In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 12.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Capricor Therapeutics
A number of hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics in the 1st quarter valued at approximately $40,000. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the third quarter worth $133,000. Main Street Financial Solutions LLC raised its holdings in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 7,500 shares during the period. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock worth $1,040,000 after purchasing an additional 13,762 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
